BerandaCRSP • NASDAQ
add
Crispr Therapeutics AG
$48,92
Setelah Jam Perdagangan Normal:(0,16%)+0,080
$49,00
Tutup: 18 Okt, 19.47.58 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$48,29
Rentang hari
$48,40 - $49,24
Rentang tahun
$37,55 - $91,10
Kapitalisasi pasar
4,17Â M USD
Volume Rata-Rata
1,03Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 517,00Â rb | -99,26% |
Biaya operasional | 19,48Â jt | 2,36% |
Laba bersih | -126,41Â jt | -62,60% |
Margin laba bersih | -24,45Â rb | -21.915,39% |
Penghasilan per saham | -1,49 | -52,04% |
EBITDA | -146,42Â jt | -62,21% |
Tarif pajak efektif | -1,03% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,00Â M | 13,21% |
Total aset | 2,34Â M | 6,50% |
Total liabilitas | 358,90Â jt | -5,80% |
Total ekuitas | 1,98 M | — |
Saham yang beredar | 85,17 jt | — |
Harga terhadap nilai buku | 2,07 | — |
Tingkat pengembalian aset | -15,83% | — |
Tingkat pengembalian modal | -16,69% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -126,41Â jt | -62,60% |
Kas dari operasi | -95,58Â jt | 28,27% |
Kas dari investasi | -126,90Â jt | -158,50% |
Kas dari pembiayaan | -466,00Â rb | -102,78% |
Perubahan kas bersih | -222,95Â jt | -321,91% |
Arus kas bebas | -55,64Â jt | 52,07% |
Tentang
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Didirikan
2013
Kantor pusat
Situs
Karyawan
407
